Scholarlink

<p>Colorectal cancer (CRC) remains a significant global health challenge, with the current therapies often being inadequate. This study investigates the potential of <i>Avicennia alba</i> (<i>A. alba</i>), a mangrove plant, as a source of new anticancer drug candidates. We employed a network pharmacology, bioinformatics approach, and in vitro experimental to explore the molecular mechanisms of action and validating activity of <i>A. alba</i> in CRC treatment. Cytotoxicity effect was also evaluated using MTT assay. Four constituents of <i>A. alba</i>—Avicenol B, Avicenol C, Avicequinone B, and Avicequinone C—were verified, leading to the identification of 10 hub genes (i.e., <i>EGFR</i>, <i>PIK3CA</i>, <i>JAK2</i>, <i>MTOR</i>, <i>JUN</i>, <i>ERBB2</i>, <i>IGF2</i>, <i>SRC</i>, <i>MDM2</i>, and <i>PARP1</i>) associated with CRC. Molecular docking and molecular dynamics simulations indicated that Avicequinone C exhibited the best docking scores and stable interactions with the top three hub genes (<i>EGFR</i>, <i>PIK3CA</i>, and <i>JAK2</i>). The interactions were characterized by π-sigma, alkyl, and conventional hydrogen bonds. <i>A. alba</i> exhibited cytotoxic activity against WiDr cell lines with an IC<sub>50</sub> of 205.96 ± 24.05&#xa0;μg/mL after treatment for 48&#xa0;h. Our findings highlight potential therapeutic targets for <i>A. alba</i> in CRC treatment and demonstrate that integrating network pharmacology, bioinformatics, and molecular docking with in vitro experimental validation is an effective strategy for discovering new therapeutic targets in drug development.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Deciphering anti-colorectal cancer potential of Avicennia alba bioactives via network pharmacology and in vitro validation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月31日

查看全文
  • Lalu Muhammad Irham,
  • Wirawan Adikusuma,
  • Didi Nurhadi Illian,
  • Maulida Mazaya,
  • Alfian Mubaraq,
  • Muhammad Ma’ruf,
  • Novi Kurnia Rizki,
  • Maya Sari Mutia,
  • Hayssam M. Ali,
  • Mohammad Basyuni

摘要

Colorectal cancer (CRC) remains a significant global health challenge, with the current therapies often being inadequate. This study investigates the potential of Avicennia alba (A. alba), a mangrove plant, as a source of new anticancer drug candidates. We employed a network pharmacology, bioinformatics approach, and in vitro experimental to explore the molecular mechanisms of action and validating activity of A. alba in CRC treatment. Cytotoxicity effect was also evaluated using MTT assay. Four constituents of A. alba—Avicenol B, Avicenol C, Avicequinone B, and Avicequinone C—were verified, leading to the identification of 10 hub genes (i.e., EGFR, PIK3CA, JAK2, MTOR, JUN, ERBB2, IGF2, SRC, MDM2, and PARP1) associated with CRC. Molecular docking and molecular dynamics simulations indicated that Avicequinone C exhibited the best docking scores and stable interactions with the top three hub genes (EGFR, PIK3CA, and JAK2). The interactions were characterized by π-sigma, alkyl, and conventional hydrogen bonds. A. alba exhibited cytotoxic activity against WiDr cell lines with an IC50 of 205.96 ± 24.05 μg/mL after treatment for 48 h. Our findings highlight potential therapeutic targets for A. alba in CRC treatment and demonstrate that integrating network pharmacology, bioinformatics, and molecular docking with in vitro experimental validation is an effective strategy for discovering new therapeutic targets in drug development.